Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Mult Scler Relat Disord ; 54: 103136, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34247104

ABSTRACT

BACKGROUND: Tight junction proteins contribute to maintenance of epithelial and endothelial barriers such as the intestinal barrier and the blood brain barrier (BBB). Increased permeability of these barriers has been linked to disease activity in MS and there is currently a lack of easily accessible biomarkers predicting disease activity in MS. AIM: To investigate whether levels of circulating tight junction proteins occludin and zonula occludens-1 (ZO-1) are associated with biomarkers of inflammation and disease activity; and to determine whether they could serve as clinical biomarkers. METHODS: We prospectively included 72 newly diagnosed patients with relapsing remitting MS or clinically isolated syndrome with no prior disease modifying therapy (DMT) use and 50 healthy controls (HCs). Patients were followed with blood samples, 3 tesla MRI, and clinical evaluation for 12 months. Occludin, ZO-1, calprotectin and soluble urokinase-type plasminogen activator receptor (suPAR) were measured by ELISA; serum neurofilament light (NfL) and IL-6 by single-molecule array (SIMOA). The mRNA expression of IFNG, IL1R1, IL10, IL1B, ARG1 and TNF was measured by quantitative real time polymerase chain reaction (qPCR) in whole blood. RESULTS: Plasma occludin levels were higher in MS patients compared with HCs. After 12 months on DMT, occludin levels were reduced by approximately 25% irrespective of 1st or 2nd line DMT (p<0.001). Furthermore, NfL and calprotectin levels were significantly reduced by 31% and 29%, respectively. Occludin and ZO-1 did not correlate with biomarkers of inflammation and did not predict disease activity at baseline or after 12 months. CONCLUSIONS: Higher levels of occludin suggest an increased permeability of the BBB and/or the intestinal barrier in MS patients. The reduction of occludin after 12 months on DMTs might reflect repair of these barriers upon treatment. However, plasma levels of ZO-1 and occludin could not predict clinical or MRI disease activity as determined by regression and ROC-curve analysis. Our results do not indicate a clear clinically relevant role for circulating tight junction proteins as biomarkers of disease activity in MS and further investigations in larger cohorts are needed to clarify this issue.


Subject(s)
Multiple Sclerosis , Tight Junction Proteins , Humans , Inflammation , Occludin , Zonula Occludens-1 Protein
2.
Mult Scler Relat Disord ; 46: 102520, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32980645

ABSTRACT

BACKGROUND: There is a lack of reliable biomarkers predicting disability and disease activity in multiple sclerosis (MS). Recent evidence suggests an involvement of intestinal and pulmonary epithelial barrier function related to immune activation and the pathophysiology of MS. Blood biomarkers of epithelial barrier function have, however, not been widely studied in MS. OBJECTIVE: To examine biomarkers of inflammation and epithelial barrier function in relapsing remitting MS (RRMS) patients compared with healthy controls (HCs), and to assess associations between biomarkers and disease activity. METHODS: A panel of 30 biomarkers were measured in serum or plasma from 49 newly diagnosed, untreated RRMS patients and 58 HCs with electrochemiluminescence or ELISA. Neurofilament light chain (NfL) was measured with single-molecule array. Validation was performed in a second independent cohort of 68 newly diagnosed, treatment naive RRMS patients and 50 HCs. Patients were divided into groups of active and inactive disease based on NfL levels and the presence of gadolinium enhancing magnetic resonance imaging lesions. RESULTS: Patients with active MS showed significantly higher serum levels of calprotectin and soluble urokinase plasminogen activator receptor compared with inactive MS in the exploratory cohort. Validation confirmed higher levels of calprotectin in active compared with inactive MS, and HCs. Biomarkers of intestinal and pulmonary epithelial barrier function did not differ significantly between groups. CONCLUSIONS: The measured biomarkers of epithelial barrier function do not seem to play a major role in the pathophysiology of MS, but serum calprotectin could represent a clinically useful biomarker of innate immune activation and disease activity.


Subject(s)
Multiple Sclerosis, Relapsing-Remitting , Multiple Sclerosis , Biomarkers , Humans , Inflammation , Multiple Sclerosis/diagnostic imaging , Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging , Neurofilament Proteins
3.
J Neuroimmunol ; 337: 577085, 2019 12 15.
Article in English | MEDLINE | ID: mdl-31655423

ABSTRACT

The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.


Subject(s)
CD4-Positive T-Lymphocytes/metabolism , Immunologic Factors/administration & dosage , Multiple Sclerosis/blood , Multiple Sclerosis/drug therapy , Natalizumab/administration & dosage , Adult , Aged , CD146 Antigen/biosynthesis , CD146 Antigen/blood , CD4-Positive T-Lymphocytes/drug effects , Cohort Studies , Female , Gene Expression , Humans , Infusions, Intravenous , Male , Middle Aged , Prospective Studies , Young Adult
4.
Mult Scler Relat Disord ; 33: 5-12, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31129415

ABSTRACT

BACKGROUND: Use of cannabis to alleviate multiple sclerosis (MS)-related symptoms is increasing. Due to strict regulations, only a minority of MS patients receive cannabis-based prescription drugs. The extent of recreational and medical cannabis use among Danes with MS is unknown. Our aim was to evaluate the prevalence of illegal and legal use of cannabis in MS patients, as well as reasons for use and perceived adverse effects. METHODS: An anonymous questionnaire was sent to all 3606 patients at the Danish Multiple Sclerosis Center, Rigshospitalet, University of Copenhagen. The questionnaire included questions about sociodemographic factors, clinical characteristics and medical or recreational cannabis use. RESULTS: Questionnaires were completed by 2244/3606 (62%), of which 2009 questionnaires from patients with MS or clinical isolated syndrome (CIS) were valid for analysis. Forty-nine percent (980/2009) had used cannabis at least once. Cannabis was used within the past year (current user) by 21%, and only 21% of those received prescribed cannabis-based medicine. Recreational use was reported by 17%. The primary reasons for use were to alleviate pain (61%), spasticity (52%) and sleep disturbances (46%). The most common adverse effects were drowsiness (30%), feeling quiet/subdued (23%) and dizziness (13%). Almost half (44%) of the non-cannabis users would consider use of cannabis to alleviate MS symptoms if the drug was legalized. CONCLUSION: This study shows that illegal cannabis use is common among Danes with MS as only 21% of the current cannabis users received prescribed cannabis-based medicine. Current cannabis users reported high efficacy in relieving pain, spasticity and sleep disturbances. In addition, only mild to moderate severity of adverse effects were reported. To the best of our knowledge, this is the most comprehensive survey of cannabis use among MS patients.


Subject(s)
Illicit Drugs , Marijuana Smoking/epidemiology , Medical Marijuana/therapeutic use , Multiple Sclerosis/drug therapy , Adult , Cannabis , Cross-Sectional Studies , Denmark , Female , Humans , Male , Middle Aged , Surveys and Questionnaires , Young Adult
5.
Mult Scler J Exp Transl Clin ; 4(4): 2055217318813183, 2018.
Article in English | MEDLINE | ID: mdl-30515298

ABSTRACT

BACKGROUND: Subtypes of white blood cell counts are known biomarkers of systemic inflammation and a high neutrophil-to-lymphocyte ratio (NLR) has been associated with several autoimmune diseases. Few studies have investigated the NLR in multiple sclerosis (MS). OBJECTIVE: To examine the association between NLR, MS and disability measured by the MS severity score (MSSS). METHODS: Patients were included from the Danish Multiple Sclerosis Biobank. Information on patient NLR was obtained just before their first treatment and clinical information was provided by the Danish Multiple Sclerosis Treatment Register. Information on NLR from controls was collected from the Danish Blood Donor Study. Patients and controls were 1:2 propensity score matched by baseline confounders. RESULTS: Propensity score matching left 740 of 743 MS patients and 1420 of 4691 controls for further analyses. Odds-ratio (OR) was 3.64 (95% confidence interval 2.87-4.60, p < 0.001) for MS disease per unit increase of logarithmically transformed NLR (ln-NLR), corresponding to an OR of 2.68 for each doubling of NLR. Mean NLR was 2.12 for patients and 1.72 for controls (p < 0.001). Ln-NLR correlated weakly with patient MSSS (R 2 = 0.019, p = 0.008). CONCLUSION: Patients with early MS had increased levels of NLR compared to healthy controls and NLR was weakly correlated with MSSS.

6.
Acta Neurol Scand ; 137(3): 363-369, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29270986

ABSTRACT

BACKGROUND: Multiple sclerosis (MS) patients are at increased risk of reduced bone mineral density (BMD) and fractures. The aetiology of bone loss in MS is unclear. Trabecular bone score (TBS) is a novel analytical tool that provides a measurement of the bone microarchitecture. Decreased TBS predicts increased fracture risk independently of BMD. To date, no studies have investigated TBS in MS patients. OBJECTIVES: To assess bone quality in MS patients by TBS and to evaluate potential risk factors that may affect BMD and TBS in patients with MS. METHODS: Two hundred sixty MS patients were included. TBS was calculated using TBS iNsight software (MediMaps® ). Multivariable regression analyses were performed with information on smoking, alcohol, glucocorticoid (GC) treatment, sun exposure, physical activity, vitamin D and BMI. RESULTS: Trabecular bone score was not significantly different from an age-matched reference population. Low TBS was associated with high age (P = .014) and smoking (P = .03). Smoking and physical inactivity were associated with low BMD in spine (P = .034, P = .032). GC treatment was not associated with TBS. CONCLUSION: We could not find altered TBS values among MS patients, suggesting that BMD alone, and not the bone microarchitecture, is affected in MS. However, larger studies are needed to verify these findings and to establish the role of TBS in MS. As in the background population, physical activity and non-smoking habits are associated with better bone health in MS.


Subject(s)
Bone Density , Bone and Bones/pathology , Image Interpretation, Computer-Assisted/methods , Multiple Sclerosis/pathology , Absorptiometry, Photon , Adult , Aged , Female , Humans , Male , Middle Aged , Regression Analysis , Risk Factors
7.
Acta Neurol Scand ; 135(1): 129-133, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27910101

ABSTRACT

BACKGROUND: Initiation of fingolimod treatment is associated with a transient decrease of heart rate, and atrioventricular (AV) conduction block may occur. OBJECTIVE: To evaluate the therapeutic effect and safety of fingolimod treatment in MS patients in Denmark with focus on cardiac and pulmonary side effects at treatment onset. MATERIALS & METHODS: We analysed data from the first 496 fingolimod-treated Danish patients, observed for at least 3 months. In a subset of 204 patients, we monitored cardiac and pulmonary adverse effects following treatment initiation. RESULTS: The overall annualized relapse rate (ARR) was 0.37 (95% CI 0.31-0.44); 0.22 (95% CI 0.03-0.81) in de novo-treated patients, 0.29 (95% CI; 0.23-0.37) in patients switching from IFN-beta or GA and 0.46 (9 5% CI 0.34-0.60) after natalizumab. In the subset of 204 patients, 8 (3.9%) required prolonged cardiac monitoring due to bradycardia and/or second-degree AV block type I. All patients recovered spontaneously. Two patients discontinued fingolimod. Eleven (5.4%) patients reported respiratory complaints and two of these patients discontinued treatment. CONCLUSIONS: Fingolimod appears to be safe and effective in MS patients in a clinical setting. Mild cardiac adverse effects occurred at a similar rate as in clinical trials.


Subject(s)
Fingolimod Hydrochloride/adverse effects , Immunosuppressive Agents/adverse effects , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Adult , Aged , Cardiotoxicity/etiology , Denmark , Female , Fingolimod Hydrochloride/therapeutic use , Heart Rate/drug effects , Humans , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Respiration/drug effects
8.
Mult Scler Relat Disord ; 10: 66-72, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27919501

ABSTRACT

BACKGROUND: Natalizumab reduces disease activity in multiple sclerosis (MS). Natalizumab binds to the very late antigen-4 and inhibits vascular cell adhesion molecule-1 (VCAM-1)-mediated transmigration of immune cells across the blood-brain-barrier. This is associated with decreased serum concentrations of soluble (s)VCAM-1 and an altered composition of immune cell-subsets in the blood. OBJECTIVE: We aimed to examine if sVCAM-1 serum concentrations and whole blood mRNA expression levels of immune activation biomarkers is associated with disease activity in natalizumab-treated MS-patients. METHODS: sVCAM-1 serum concentrations and whole blood mRNA expression were measured in blood samples from untreated RRMS-patients and from two independent groups of natalizumab-treated patients. RESULTS: sVCAM-1 serum concentrations and whole blood expression of HLX1 and IL1B mRNA were lower, whereas expression of EBI3 mRNA was higher in natalizumab-treated MS-patients. Five genes were differentially expressed in clinically unstable natalizumab-treated MS-patients in the discovery but not in the validation group. CONCLUSION: Decreased serum concentrations of sVCAM-1 and altered whole blood mRNA expression levels of a panel of immunomarkers, associated with natalizumab-treatment, are not sensitive markers of MS disease activity. However, decreased expression of pro-inflammatory HLX1 and IL1B and increased expression of immunoregulatory EBI3 may indicate a less pathogenic immune activation status in natalizumab-treated MS.


Subject(s)
Immunologic Factors/therapeutic use , Multiple Sclerosis/blood , Multiple Sclerosis/drug therapy , Natalizumab/therapeutic use , RNA, Messenger/blood , Vascular Cell Adhesion Molecule-1/blood , Adult , Biomarkers, Pharmacological/blood , Cohort Studies , Female , Glucocorticoids/therapeutic use , Homeodomain Proteins/blood , Humans , Interleukin-1beta/blood , Interleukins/blood , Male , Middle Aged , Minor Histocompatibility Antigens/blood , Multiple Sclerosis/immunology , Time Factors , Transcription Factors/blood
9.
Mult Scler Relat Disord ; 9: 104-9, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27645354

ABSTRACT

BACKGROUND: Epidemiological studies suggest an important role for environmental factors in developing multiple sclerosis (MS). Furthermore several studies have indicated that the effect of environmental factors may be especially pronounced in adolescents. Recently only one study investigated and found that shift work at young age is associated with an increased risk of developing MS. In this study we focused on the effect of shift work in the vulnerable period between 15-19 years. OBJECTIVE: The aim of this study was to investigate the association between shift work at young age and the risk of developing MS. METHODS: We performed a large case-control study including 1723 patients diagnosed with MS and 4067 controls. MS patients were recruited from the Danish Multiple Sclerosis Biobank and controls from The Danish Blood Donor Study. Information on working patterns and lifestyle factors was obtained using a comprehensive lifestyle-environmental factor questionnaire with participants enrolled between 2009 and 2014. Logistic regression models were used to investigate the association between shift work at age 15-19 years and the subsequent risk of MS and were controlled for effects due to established MS risk factors. RESULTS: We found a statistically significant association when total numbers of night shifts were compared with non-shift workers. For every additional 100 night shifts the odds ratio (OR) for MS was 1.20 (95% confidence interval (CI), 1.08-1.34, p=0.001). Increasing intensity of shift work also increased MS risk. For every additional night per month the OR was 1.04 (95% CI, 1.01-1.06, p=0.002). Duration of shift work in years was not associated with risk of MS. CONCLUSION: This study supports a statistically significant association between shift work at age 15-19 years and MS risk.


Subject(s)
Employment , Multiple Sclerosis/epidemiology , Adult , Age Factors , Case-Control Studies , Denmark/epidemiology , Female , Humans , Logistic Models , Male , Odds Ratio , Risk Factors
10.
Mult Scler ; 21(12): 1557-65, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25623251

ABSTRACT

BACKGROUND: Patients with multiple sclerosis (MS) are at increased risk of reduced bone mineral density (BMD). A contributing factor might be treatment with high-dose glucocorticoids (GCs). OBJECTIVES: The objective of this paper is to assess bone mass in patients with MS and evaluate the importance of short-term, high-dose GC treatment and other risk factors that affect BMD in patients with MS. METHODS: A total of 260 patients with MS received short-term high-dose GC treatment and had their BMD measured by dual x-ray absorptiometry. BMD was compared to a healthy age-matched reference population (Z-scores). Data regarding GCs, age, body mass index (BMI), serum 25(OH)D, disease duration and severity were collected retrospectively and analysed in a multiple linear regression analysis to evaluate the association between each risk factor and BMD. RESULTS: Osteopenia was present in 38% and osteoporosis in 7% of the study population. Mean Z-score was significantly below zero, indicating a decreased BMD in our MS patients. Multiple linear regression analysis showed no significant association between GCs and BMD. In contrast, age, BMI and disease severity were independently associated with both lumbar and femoral BMD. CONCLUSION: Reduced BMD was prevalent in patients with MS. GC treatment appears not to be the primary underlying cause of secondary osteoporosis in MS patients.


Subject(s)
Bone Density/drug effects , Glucocorticoids/adverse effects , Multiple Sclerosis, Chronic Progressive/drug therapy , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Absorptiometry, Photon , Adult , Age Factors , Aged , Body Mass Index , Bone Density/physiology , Female , Glucocorticoids/administration & dosage , Humans , Male , Middle Aged , Multiple Sclerosis, Chronic Progressive/blood , Multiple Sclerosis, Relapsing-Remitting/blood , Severity of Illness Index , Young Adult
11.
Acta Neurol Scand ; 130(4): 268-75, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24943672

ABSTRACT

OBJECTIVE: Single nucleotide polymorphisms (SNPs) in the genes encoding interferon response factor (IRF)-5, IRF-8 and glypican-5 (GPC5) have been associated with disease activity in multiple sclerosis (MS) patients treated with interferon (IFN)-ß. We analysed whether SNPs in the IRF5, IRF8 and GPC5 genes are associated with clinical disease activity in MS patients beginning de novo treatment with IFN-ß. METHODS: The SNPs rs2004640, rs3807306 and rs4728142 in IRF5, rs13333054 and rs17445836 in IRF8 and rs10492503 in GPC5 were genotyped in 575 patients with relapsing-remitting MS followed prospectively after the initiation of their first treatment with IFN-ß. RESULTS: 62% of patients experienced relapses during the first 2 years of treatment, and 32% had disability progression during the first 5 years of treatment. Patients with a pretreatment annualized relapse rate >1 had an increased risk of relapse (hazard ratio 1.53, 95% confidence interval 1.24-1.90) and progression (hazard ratio 1.48, 95% confidence interval 1.10-1.99) on treatment and patients with breakthrough relapses in the form of relapses during the first 2 years of treatment had an increased risk of progression during the first 5 years of treatment (hazard ratio 2.04, 95% confidence interval 1.47-2.85).The gene variants in IRF5, IRF8 and GPC5 were not associated with risk of relapse or disease progression. CONCLUSIONS: Pretreatment relapse rate and clinical disease activity during the first 2 years of treatment may be associated with disease progression in MS patients treated with IFN-ß. Genetic analysis of the studied gene variants do not provide additional information.


Subject(s)
Genetic Predisposition to Disease/genetics , Glypicans/genetics , Interferon Regulatory Factors/genetics , Multiple Sclerosis, Relapsing-Remitting/genetics , Adult , Disease Progression , Female , Humans , Interferon-beta/therapeutic use , Male , Middle Aged , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Polymorphism, Single Nucleotide , Recurrence
12.
Rheumatol Int ; 34(10): 1401-8, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24719229

ABSTRACT

This study aimed to demonstrate possible associations between genetic polymorphisms in Toll-like receptor 3, interferon induced with helicase C domain 1 (IFIH1) and DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 and systemic lupus erythematosus (SLE), including the phenotypes lupus nephritis and malar rash, as well as the presence of autoantibodies against nucleic acid-containing complexes. Genotyping was carried out in two Danish cohorts [Copenhagen (CPH) and Odense (ODE)] totaling 344 patients and was compared with 641 previously genotyped healthy controls. In the ODE cohort, the patients were only genotyped for the rs1990760 polymorphism of IFIH1. Single nucleotide polymorphisms (SNPs) were determined by a multiplex bead-based assay (CPH cohort) or real-time PCR (ODE cohort). Associations were investigated using the Cochran-Armitage trend test. The odds ratio (OR) for minor allele homozygotes versus major allele homozygotes suggested a protective effect of the IFIH1 rs1990760 SNP for SLE in the ODE cohort [OR 0.52, 95 % confidence intervals (95 % CI) 0.31-0.88, Pcorr. = 0.05] but not in the CPH cohort, although the OR suggested a trend in the same direction, and when combining the two patient cohorts, ORs were 0.57, 95 % CI 0.37-0.88. None of the other investigated polymorphisms showed any association with SLE. Regarding phenotypes, we found a statistically significant association between rs1990760 and malar rash in the CPH cohort, with ORs suggesting a protective effect (OR 0.28, 95 % CI 0.13-0.62 for heterozygotes and OR 0.11, 95 % CI 0.03-0.41 for homozygotes, Pcorr. = 0.0001). There were no significant associations between rs1990760 and presence of anti-dsDNA, anti-U1RNP, or anti-Smith antibodies. Our study supports previous findings of an association between the rs1990760 polymorphism of IFIH1 and SLE and indicates that this SNP may also be associated with malar rash in SLE patients although this finding needs confirmation.


Subject(s)
DEAD-box RNA Helicases/genetics , Lupus Erythematosus, Systemic/genetics , Polymorphism, Single Nucleotide , Receptors, Retinoic Acid/genetics , Toll-Like Receptor 3/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Alleles , DEAD Box Protein 58 , Female , Genetic Association Studies , Genetic Predisposition to Disease , Genotype , Humans , Interferon-Induced Helicase, IFIH1 , Male , Middle Aged , Phenotype , Receptors, Immunologic , Young Adult
13.
Acta Neurol Scand ; 129(1): 27-31, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23668375

ABSTRACT

OBJECTIVE: The chemokine receptor CCR5 may be important for the recruitment of pathogenic T cells to the CNS in multiple sclerosis (MS). We hypothesized that this chemokine receptor might still be important for T-cell migration during treatment with anti-very late antigen (VLA)-4 antibody. We therefore analysed whether natalizumab-treated MS patients carrying the CCR5 Δ32 deletion allele, which results in reduced expression of CCR5 on the cell surface, had lower disease activity. METHODS: CCR5 Δ32 was analysed in 212 natalizumab-treated MS patients. RESULTS: CCR5 Δ32 status had no significant impact on the frequency of relapses 1 year prior to natalizumab treatment or during the first 48 weeks of treatment. The multiple sclerosis severity score (MSSS) was significantly lower at baseline in patients carrying CCR5 Δ32 (P = 0.031). CONCLUSIONS: CCR5 Δ32 is not associated with lower disease activity in MS patients treated with natalizumab. We found lower MSSS scores in patients carrying CCR5 Δ32 compared with the remaining patients, which is consistent with previous studies reporting an association with a more favourable disease course. Further studies are, however, needed before the relationship between CCR5 Δ32 and disease activity in MS can be definitely established.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Receptors, CCR5/genetics , Adult , Alleles , Disease Progression , Female , Follow-Up Studies , Genotype , Humans , Integrin alpha4beta1/antagonists & inhibitors , Male , Multiple Sclerosis, Relapsing-Remitting/genetics , Natalizumab , Prospective Studies , Receptors, CCR5/physiology , Sequence Deletion , Severity of Illness Index , Treatment Outcome
14.
Genes Immun ; 11(4): 279-93, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20072140

ABSTRACT

Rat chromosome 1 harbors overlapping quantitative trait loci (QTL) for cytokine production and experimental models of inflammatory diseases. We fine-dissected this region that regulated cytokine production, myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE), anti-MOG antibodies and pristane-induced arthritis (PIA) in advanced intercross lines (AILs). Analysis in the tenth and twelfth generation of AILs resolved the region in two narrow QTL, Eae30 and Eae31. Eae30 showed linkage to MOG-EAE, anti-MOG antibodies and levels of interleukin-6 (IL-6). Eae31 showed linkage to EAE, PIA, anti-MOG antibodies and levels of tumor necrosis factor (TNF) and IL-6. Confidence intervals defined a limited set of potential candidate genes, with the most interesting being RGMA, IL21R and IL4R. We tested the association with multiple sclerosis (MS) in a Nordic case-control material. A single nucleotide polymorphism in RGMA associated with MS in males (odds ratio (OR)=1.33). Polymorphisms of RGMA also correlated with changes in the expression of interferon-gamma (IFN-gamma) and TNF in cerebrospinal fluid of MS patients. In IL21R, there was one positively associated (OR=1.14) and two protective (OR=0.87 and 0.68) haplotypes. One of the protective haplotypes correlated to lower IFN-gamma expression in peripheral blood mononuclear cells of MS patients. We conclude that RGMA and IL21R and their pathways are crucial in MS pathogenesis and warrant further studies as potential biomarkers and therapeutic targets.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental/genetics , Membrane Proteins/genetics , Multiple Sclerosis/genetics , Nerve Tissue Proteins/genetics , Receptors, Interleukin-21/genetics , Animals , Female , GPI-Linked Proteins , Genetic Linkage , Haplotypes , Male , Polymorphism, Single Nucleotide , Quantitative Trait Loci , Rats
15.
Eur J Neurol ; 16(3): 420-3, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19364368

ABSTRACT

INTRODUCTION: Previous studies of natalizumab (Tysabri) in relapsing multiple sclerosis (MS) patients have included patients with moderate disease activity. We studied a patient population with high disease activity. PATIENTS AND METHODS: We analyzed data from 234 consecutive, natalizumab-treated patients, followed for at least 3 months. Three groups of patients were eligible for natalizumab therapy: patients with two or more documented relapses or sustained increase of 2 EDSS points on disease modifying therapy (DMT) in the previous year; patients switching from mitoxantrone; and patients with very active MS as de novo therapy. RESULTS: During a median observation time of 11.3 months (range 3.0-21.5) the annualized relapse rate decreased to 0.68 from a pre-treatment rate of 2.53 (73% reduction). We assessed the annualized relapse rate in three subgroups: (i) 0.83 in 14 (6.0%) de novo treated patients; (ii) 0.71 in 175 (74.8%) patients with >or=2 relapses or sustained increase in EDSS of >or=2 points on a first-line DMT; and (iii) 0.56 in 45 (19.2%) patients switching from mitoxantrone. Nine anaphylactoid reactions, two severe, were reported. Out of 215 patients 7 (3%) were persistently positive for antibodies to natalizumab. CONCLUSIONS: Tysabri appears to be effective in MS patients with high disease activity, but the relapse rate was higher than in the pivotal study after the first treatment year. This is likely to reflect differences in disease activity before the initiation of natalizumab treatment.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Neuroprotective Agents/therapeutic use , Adolescent , Adult , Anaphylaxis/chemically induced , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal, Humanized , Denmark , Disease Progression , Enzyme-Linked Immunosorbent Assay , Humans , Middle Aged , Mitoxantrone/therapeutic use , Multiple Sclerosis, Relapsing-Remitting/immunology , Natalizumab , Neuroprotective Agents/adverse effects , Neuroprotective Agents/immunology , Recurrence , Severity of Illness Index , Treatment Outcome , Young Adult
16.
Ugeskr Laeger ; 160(26): 3909-12, 1998 Jun 22.
Article in Danish | MEDLINE | ID: mdl-9656831

ABSTRACT

The objective was to assess the present condition of patients previously treated with neurosurgical procedures for trigeminal neuralgia (TN). Between 1976 and 1991, 383 patients were treated for TN at the Department of Neurosurgery, Hvidovre Hospital. The latest surgical intervention performed was radiofrequency coagulation (64%), neurectomy (18%), alcohol block (16%), trigeminal tractotomy (1%), and microvascular decompression (1%). Questionnaires were sent to 316 patients treated neurosurgically for trigeminal neuralgia during the 16 year period. After radiofrequency coagulation, neurectomy and alcohol block, 83, 51 and 42% respectively experienced a pain free postoperative period. At present 49, 17 and 18% were without pain and 33, 21 and 36% had less pain compared with the preoperative state. Sequelae were described in 65, 57 and 49% of the patients. The four most common sequelae were hypaesthesia, paraesthesia, eye complaints, and dysaesthesia. If relevant pharmacotherapy has been tried without benefit, radiofrequency coagulation may still be considered as a treatment of trigeminal neuralgia.


Subject(s)
Electrocoagulation , Ethanol/administration & dosage , Nerve Block , Neurosurgical Procedures , Trigeminal Neuralgia/surgery , Adult , Aged , Decompression, Surgical , Female , Humans , Male , Middle Aged , Nerve Block/methods , Neurosurgical Procedures/methods , Retrospective Studies , Surveys and Questionnaires , Trigeminal Nerve/surgery , Trigeminal Neuralgia/drug therapy , Trigeminal Neuralgia/therapy
17.
Clin J Pain ; 12(4): 311-5, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8969876

ABSTRACT

OBJECTIVES: We wished to assess the present condition of patients previously treated with a neurosurgical procedure or procedures for trigeminal neuralgia (TN) in 383 patients treated between 1976 and 1991, for TN at the Department of Neurosurgery, Hvidovre Hospital. Of these, 67 were lost to follow-up. The latest surgical intervention performed was radiofrequency coagulation (RFC) (64%), neurectomy (18%), alcohol block (16%), trigeminal tractotomy (1%), and microvascular decompression (1%); 72% of patients underwent only one neurosurgical procedure. METHODS: Questionnaires were sent to 316 patients treated neurosurgically for TN during the 16-year period; 288 (91%) patients responded. The follow-up period varied from 1 to 16 years (mean 8 years). Outcome measures were effect of RFC, neurectomy, and alcohol block; present pain conditions; and sequelae. RESULTS: After RFC, neurectomy, and alcohol block, 83, 51, and 42% of patients, respectively, experienced a pain-free postoperative period; 49, 78, and 84% of these patients had recurrence of pain. At present, 49, 17, and 18% are pain-free and 33, 21, and 36% now have less pain than they did preoperatively. Temporary or permanent analgesics for facial pain were required in 41, 72, and 69% of the patients. Sequelae were described by 65, 57, and 49% of the patients. The four most common sequelae were hypoesthesia, paresthesia, eye complaints, and dysesthesia. CONCLUSION: If relevant pharmacotherapy has been tried without benefit, RFC may still be considered as a treatment for TN.


Subject(s)
Neurosurgery , Trigeminal Neuralgia/surgery , Adult , Aged , Aged, 80 and over , Catheter Ablation , Ethanol/therapeutic use , Female , Humans , Male , Middle Aged , Nerve Block , Palliative Care , Postoperative Complications , Recurrence , Treatment Outcome , Trigeminal Neuralgia/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...